Hainan Shuangcheng Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN

P/E

227.56

P/S

15.66

EPS

0.05

Div Yield, %

—

Shrs. gr., 5y

0.23%

Rev. gr., 5y

-2.88%

Revenues

277m

+58.87%

Net income

19m

CFO

61m

Dividend

Mar 10, 20150.15 CNY/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Profile

Hainan Shuangcheng Pharmaceuticals Co., Ltd. operates internationally, undertaking the entire lifecycle of synthetic peptide drugs and active pharmaceutical ingredients (APIs), from initial research and development through manufacturing to global market distribution. Its extensive product portfolio encompasses a wide array of injectable medications, including somatostatin, thymosin, clindamycin hydrochloride, thymopentin, L-carnitine, uranin hydrobromide, inosine, cyclophosphine adenosine, motidine, scopolamine, and sodium ferulate. Additionally, the company provides vitamin B6. Founded in 2000, the firm is headquartered in Haikou, People's Republic of China.

URL

http://www.shuangchengmed.com/

IPO date

Aug 08, 2012

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2023‑00	2022‑12	2022‑00	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT